Goldman Sachs on Biogen (BIIB): 'we remain positive on BIIB's opportunity to address the early AD market'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $398.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
